A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, chemotherapy or radiation, the study found.

This phase 2 study builds on previous landmark research, in which colorectal cancer patients receiving the immunotherapy drug dostarlimab experienced complete tumor remission. In recognition of ...

Dostarlimab, a programmed death receptor-1 (PD-1)-blocking antibody, completely eradicated rectal cancer tumors without the need for surgery, radiation treatment or chemotherapy.

Adding dostarlimab to platinum-based chemotherapy and niraparib improved PFS in patients with advanced ovarian cancer.

“For as long as cancer treatment has existed ... It’s all thanks to dostarlimab, a drug initially discovered by AnaptysBio, and that is being manufactured and brought to market by ...

A new study in the New England Journal of Medicine suggests that some people with early stage cancers may be able to skip surgery after being treated with the immunotherapy drug dostarlimab.

(2016) for its economic base case. The NHS Clinical Lead for the Cancer Drugs Fund reported that 262 people have had dostarlimab with carboplatin and paclitaxel since it has been in the Cancer Drugs ...

For a limited group of cancer patients who have solid ... Diaz Jr. and Dr. Andrea Cercek, decided to give dostarlimab, an immunotherapy drug, on its own. The result was stunning, and could bring ...